Thursday, August 13, 2026 produced a heavy slate of fresh Wall Street upgrades spanning medical technology, consumer staples, specialty retail, energy and enterprise software. That breadth matters because the macro backdrop remains restrictive. The Federal Open Market Committee held the federal funds target range at 3.50% to 3.75% on July 29, 2026, and the CME Group FedWatch tool now assigns roughly an 80% probability to no rate cuts through 2026. With policy on pause, single-name catalysts — new analyst calls, product-cycle shifts and cost or margin surprises — are doing more work than any macro tailwind. The five names below all received notable Buy-equivalent upgrades on August 13 and screen as candidates worth watching heading into Friday's session.
Abbott Laboratories (ABT) — Medtech setup improving into 2027
Abbott, the diversified medical products maker whose four segments span diagnostics, medical devices, established pharmaceuticals and nutrition, drew a notable upgrade on August 13. Wolfe Research analyst Mike Polark lifted the stock from Peer Perform to Outperform with a $130 price target, arguing in a note titled "ABT: 2027 Setup Seems AB(i)T Better" that six catalysts are lining up, including offense in electrophysiology as the Volt PFA catheter moves to full U.S. launch and a recovery in Libre continuous glucose monitors back toward 10%+ growth on easy comps and potential Medicare coverage.
Shares traded at $110.72 on August 13, down 0.18%, with a market cap of $191.6 billion and a trailing P/E of 35.59. The 52-week range is $81.97 to $137.49. Consensus is Strong Buy, with all 12 tracked analysts bullish, an average target of $122, a median of $120, a high of $143 and a low of $112.
Risks: Diagnostics is still lapping the COVID testing runoff, Libre reimbursement decisions may slip, and Volt PFA faces entrenched competition from Boston Scientific and Johnson & Johnson. On July 28, 2026, UBS analyst Patrick Wood trimmed his ABT target from $135 to $125 while keeping a Buy, a reminder that even bulls are marking down near-term expectations.
Keurig Dr Pepper (KDP) — Coffee outlook finally turning
Keurig Dr Pepper, the North American beverage giant behind Keurig single-serve coffee and a soft drink stable led by Dr Pepper, Snapple and Canada Dry, was upgraded from Hold to Buy at HSBC on August 13 with the price target raised to $40 from $37. The call cited an improving coffee outlook after several quarters of pod-volume softness and continued momentum in soft drinks, where innovation and pricing are offsetting coffee weakness.
Shares traded at $30.91 on August 13, up 4.55%, with a market cap of $42.0 billion and a trailing P/E of 31.10. The 52-week range is $24.88 to $35.94. Consensus is Strong Buy, with 5 of 6 tracked analysts bullish, an average target of $36.83, a median of $37.50, a high of $39 and a low of $32.
Risks: U.S. coffee volumes could stall if pod attach rates keep sliding, private-label competition remains fierce in ready-to-drink, and green-coffee input costs are volatile. Evercore ISI's Robert Ottenstein reiterated an In-Line rating with a $32 target on August 7, 2026, viewing the coffee recovery as still unproven.
Five Below (FIVE) — Discount retail with a viral tailwind
Five Below, the extreme-value chain selling merchandise mostly under $5, was the day's most dramatic call. On August 13, Jefferies analyst Randal Konik upgraded the stock from Hold to Buy and raised his price target to $350 from $210, citing structural improvements to the model and momentum from the viral squishy-toy category. Mizuho and Bernstein also raised their price targets on the stock this week, and UBS reiterated a Buy at $285.
Shares traded at $244.30 on August 13, up 2.59%, with a market cap of $13.5 billion and a trailing P/E of 30.85. The 52-week range is $131.52 to $251.63. Consensus is Strong Buy, with 9 of 12 tracked analysts bullish, an average target of $264.25, a median of $255, a high of $350 and a low of $220.
Risks: Value-retail traffic is sensitive to lower-income consumer stress, novelty categories like squishy toys can fade quickly, and shrink remains a margin overhang. Wolfe Research moved the other way on August 13, downgrading FIVE to Peer Perform on concerns about slowing top-line growth.
SM Energy (SM) — Multi-basin oil producer with fresh cost tailwinds
SM Energy, the independent exploration and production company operating in the Midland, Uinta and DJ basins, was upgraded from Equal Weight to Overweight at Wells Fargo on August 13, with analyst Sam Margolin raising his price target to $47 from $32. Wells Fargo cited an easing applied net-asset-value discount, better well cost trends across all three basins, and a higher front-loaded oil weighting in Uinta activity assumptions at the corporate level.
Shares traded at $32.04 on August 13, down 1.17%, with a market cap of $7.7 billion and a trailing P/E of 8.33. The 52-week range is $17.45 to $35.88. Consensus is Strong Buy, with 7 of 9 tracked analysts bullish, an average target of $40.33, a median of $39, a high of $52 and a low of $32.
Risks: WTI crude weakness would compress cash flow, integration of the Uinta acreage adds execution risk, and hedging can cap upside in a rally. Susquehanna's Charles Minervino maintained a Neutral rating at a $32 target on July 21, 2026, reflecting a more cautious view of SM's basin mix.
Salesforce (CRM) — Enterprise software with concerns "overblown"
Salesforce, the customer relationship management platform whose Data Cloud and Agentforce products anchor its AI push, saw JPMorgan analyst Mark Murphy resume coverage on August 13 with an Overweight rating and a $250 December 2027 price target. JPMorgan argued that concerns around consumption pricing, AI monetization and macro-driven software spend are overblown at current levels.
Shares traded at $197.19 on August 13, up 2.00%, with a market cap of $161.5 billion and a trailing P/E of 22.57. The 52-week range is $146.32 to $269.11. Consensus is Buy, with 8 of 15 tracked analysts bullish, an average target of $235.40, a median of $225, a high of $400 and a low of $173.
Risks: Consumption transitions can be lumpy for revenue reporting, seat growth has been decelerating, and Microsoft Dynamics plus Copilot remain competitive threats. Bernstein analyst Mark Moerdler carries the low $173 target with an Underperform rating dated May 28, 2026, arguing that AI-driven productivity gains could reduce license demand.
Found this helpful? Share it with others.